Our Principal, Yolanda Wang, just returned from the 1st China Pharmaceutical Innovation Conference (CPIC 2026) in Shanghai, held from July 22–24!

It was a pleasure to attend CPIC 2026 together with fellow HKBMIA members and connect with biotech innovators from around the world. Many thanks to HKBMIA for the invitation and the opportunity to engage with industry partners. Hong Kong continues to play an important role in connecting Mainland China with the global life sciences community.

Bringing together over 10,000 participants, CPIC highlighted the strong momentum behind cross-border biopharma innovation and collaboration. It was great to see so many discussions focused on advancing healthcare innovation and building new partnerships across borders. The strong presence of AI-related healthcare and drug development initiatives was particularly impressive and reflected the rapid evolution of China’s innovation ecosystem. As IP professionals, we are reminded of the important role that IP plays in supporting innovation and bringing new technologies to market.

我们的过去活动

Jennifer Che and Pauli Wong Co-Teach Advanced Patent Skills Seminar at HKU-TEC

2026年10月15日

Pauli Wong gave a talk at Hong Kong Life Sciences Society (HKLSS)

2026年10月10日

BioHK2026 | Biotech IP in practice

2026年9月16日

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Recommended Insights

Miss the 12-month Filing Deadline? China Finally Allows Patent Applicants to Restore, Add, or Correct a Priority Claim

2024年4月15日
Three major 'remedial’ systems taken from the PCT Regulations have been introduced in the third revision of the Implementation Regulations of the Chinese Patent Law in 2023 (hereinafter referred to as the "Implementation Regulations"). We previously discussed one of these remedial systems, Incorporation by Reference based on Rule 45 of the Implementation Regulations, which allows […]
阅读更多 >

How Smart is a "Skilled Person in the Art"?

2022年4月11日
Let’s start with a riddle: can you name a person who has read every book, every journal, conducted every known experiment, and is knowledgeable about every single patent prosecution / litigation in the world? The answer? A “skilled person in the art.” This person is also known as a “person having ordinary skill in the […]
阅读更多 >

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

2023年1月4日
Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]
阅读更多 >

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]
阅读更多 >
Top crossarrow-right